Peripheral T-cell lymphoma with involvement of the expanded mantle zone. 2006

Ida Münster Ikonomou, and Anne Tierens, and Gunhild Troen, and Hege Vangstein Aamot, and Sverre Heim, and Grete F Lauritzsen, and Helen Vålerhaugen, and Jan Delabie
Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway. ida.m.munster.ikonomou@radiumhospitalet.no

Peripheral T-cell lymphoma (PTCL) with a nodular architecture is rare. Recently, two variants have been described with infiltration of the B-cell follicle, one variant that localizes to the marginal zone with a so-called perifollicular growth pattern, and a variant that localizes to the germinal center. These lymphomas have a CD4+ phenotype and may express Bcl-6. We have studied five similar cases of PTCL with involvement of the B-cell follicle. However, our cases differ from the cases previously described by their predominant and frequently patchy involvement of the expanded mantle zone of the B-cell follicle at onset. Later biopsies in three of the cases show diffuse infiltration of the lymph node, without features of angioimmunoblastic TCL (AILT). All cases expressed Bcl-6 in addition to CD4. Cytogenetics was available in four of the cases but revealed no recurrent chromosomal aberrations or changes associated with other types of PTCL. No mutations of the BCL-6 gene were observed. Together, the cases seem to have an intermediately aggressive clinical behavior. Whether our cases are part of a spectrum of PTCLs that encompasses previously described variants with predominant marginal zone or germinal center infiltration or they represent a separate T-cell lymphoma type remains to be demonstrated by a study of more of such cases.

UI MeSH Term Description Entries
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

Ida Münster Ikonomou, and Anne Tierens, and Gunhild Troen, and Hege Vangstein Aamot, and Sverre Heim, and Grete F Lauritzsen, and Helen Vålerhaugen, and Jan Delabie
October 2008, Virchows Archiv : an international journal of pathology,
Ida Münster Ikonomou, and Anne Tierens, and Gunhild Troen, and Hege Vangstein Aamot, and Sverre Heim, and Grete F Lauritzsen, and Helen Vålerhaugen, and Jan Delabie
April 2013, Annals of oncology : official journal of the European Society for Medical Oncology,
Ida Münster Ikonomou, and Anne Tierens, and Gunhild Troen, and Hege Vangstein Aamot, and Sverre Heim, and Grete F Lauritzsen, and Helen Vålerhaugen, and Jan Delabie
July 2019, American journal of clinical pathology,
Ida Münster Ikonomou, and Anne Tierens, and Gunhild Troen, and Hege Vangstein Aamot, and Sverre Heim, and Grete F Lauritzsen, and Helen Vålerhaugen, and Jan Delabie
November 1986, Cancer,
Ida Münster Ikonomou, and Anne Tierens, and Gunhild Troen, and Hege Vangstein Aamot, and Sverre Heim, and Grete F Lauritzsen, and Helen Vålerhaugen, and Jan Delabie
April 2010, Journal of bronchology & interventional pulmonology,
Ida Münster Ikonomou, and Anne Tierens, and Gunhild Troen, and Hege Vangstein Aamot, and Sverre Heim, and Grete F Lauritzsen, and Helen Vålerhaugen, and Jan Delabie
March 2011, Journal of hematopathology,
Ida Münster Ikonomou, and Anne Tierens, and Gunhild Troen, and Hege Vangstein Aamot, and Sverre Heim, and Grete F Lauritzsen, and Helen Vålerhaugen, and Jan Delabie
March 2012, Revista espanola de enfermedades digestivas,
Ida Münster Ikonomou, and Anne Tierens, and Gunhild Troen, and Hege Vangstein Aamot, and Sverre Heim, and Grete F Lauritzsen, and Helen Vålerhaugen, and Jan Delabie
June 2015, Postepy dermatologii i alergologii,
Ida Münster Ikonomou, and Anne Tierens, and Gunhild Troen, and Hege Vangstein Aamot, and Sverre Heim, and Grete F Lauritzsen, and Helen Vålerhaugen, and Jan Delabie
April 2002, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Ida Münster Ikonomou, and Anne Tierens, and Gunhild Troen, and Hege Vangstein Aamot, and Sverre Heim, and Grete F Lauritzsen, and Helen Vålerhaugen, and Jan Delabie
May 1998, British journal of haematology,
Copied contents to your clipboard!